Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) EVP Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, October 12th. The stock was sold at an average price of $158.46, for a total value of $31,692.00. Following the completion of the sale, the executive vice president now owns 25,172 shares of the company’s stock, valued at $3,988,755.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Michael Patrick Miller also recently made the following trade(s):

  • On Friday, September 14th, Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $165.20, for a total value of $33,040.00.
  • On Tuesday, August 14th, Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals stock. The stock was sold at an average price of $175.70, for a total value of $35,140.00.

NASDAQ JAZZ opened at $157.88 on Wednesday. The company has a market cap of $10.16 billion, a PE ratio of 16.51, a PEG ratio of 0.92 and a beta of 1.04. Jazz Pharmaceuticals PLC has a 52 week low of $128.58 and a 52 week high of $184.00. The company has a quick ratio of 3.62, a current ratio of 3.76 and a debt-to-equity ratio of 0.54.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported $3.49 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.23 by $0.26. The firm had revenue of $500.48 million during the quarter, compared to the consensus estimate of $469.85 million. Jazz Pharmaceuticals had a return on equity of 25.47% and a net margin of 24.20%. On average, equities analysts anticipate that Jazz Pharmaceuticals PLC will post 11.7 earnings per share for the current fiscal year.

JAZZ has been the subject of a number of research analyst reports. BidaskClub upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 21st. B. Riley lifted their target price on Jazz Pharmaceuticals from $211.00 to $219.00 and gave the stock a “buy” rating in a report on Tuesday, June 26th. Wells Fargo & Co reiterated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Monday, July 2nd. Citigroup lifted their target price on Jazz Pharmaceuticals from $162.00 to $205.00 and gave the stock a “buy” rating in a report on Tuesday, July 10th. Finally, Zacks Investment Research downgraded Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 10th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the stock. Jazz Pharmaceuticals has an average rating of “Buy” and an average price target of $193.32.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Tdam USA Inc. increased its holdings in shares of Jazz Pharmaceuticals by 14.8% during the second quarter. Tdam USA Inc. now owns 2,818 shares of the specialty pharmaceutical company’s stock valued at $486,000 after acquiring an additional 363 shares in the last quarter. Xact Kapitalforvaltning AB boosted its position in shares of Jazz Pharmaceuticals by 2.6% during the first quarter. Xact Kapitalforvaltning AB now owns 14,606 shares of the specialty pharmaceutical company’s stock valued at $2,205,000 after buying an additional 374 shares during the last quarter. Adell Harriman & Carpenter Inc. boosted its position in shares of Jazz Pharmaceuticals by 3.0% during the second quarter. Adell Harriman & Carpenter Inc. now owns 13,790 shares of the specialty pharmaceutical company’s stock valued at $2,376,000 after buying an additional 400 shares during the last quarter. GAM Holding AG boosted its position in shares of Jazz Pharmaceuticals by 1.1% during the second quarter. GAM Holding AG now owns 38,733 shares of the specialty pharmaceutical company’s stock valued at $6,674,000 after buying an additional 433 shares during the last quarter. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its position in shares of Jazz Pharmaceuticals by 28.2% during the second quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,139 shares of the specialty pharmaceutical company’s stock valued at $369,000 after buying an additional 470 shares during the last quarter. Hedge funds and other institutional investors own 92.52% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Further Reading: What is the yield curve?

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.